June 15, 2021 7:31am
For the dropping of many of the sectors pricing elevations – it’s coming, minimize your impact!
Pre-open indications: 5 BUYs: AGTC, CLLS, GBT, VSTM, QURE; 1 SELLS: SAGE; 1 Maintain SELLs: BSTG
My version of the morning’s “indications” is about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session
Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!
Dow futures are UP +0.01% (+2 points), S&P futures are UP +0.09% (+4 point) and NASDAQ futures are UP +0.12% (+18 points)
U.S. stock index futures made modest gains in pre-market trade as investors await the Fed’s two-day policy meeting
European stocks traded in positive territory
Asia-Pacific were mostly higher with Japanese and Australian stocks leading gains regionally,
Data Docket: The Federal Reserve’s two-day policy meeting starts today, and it’s a focal point for the markets this week. Other inflation gauges will be released:
- The Producer Price Index — which measure the prices paid to producers as opposed to prices on the consumer level — is expected to rise 0.5% in May, according to estimates. The core PPI — which excludes volatile items like foods, energy and trade services — is also estimated to increase 0.5%.
- May’s retail sales data are also being release at 8:30 a.m. ET. Economists polled are expecting a drop of 0.6% for last month. Excluding autos, economists expect May’s retail sales rose 0.5%. Retail sales in April were unchanged as the boost from stimulus checks faded.
Henry’omics:
Stock futures were up but basically flat with very few stand-out pre-market performers.
The Fed meeting: the central bank is not expected to take any action. However, commentary on interest rates, inflation and the economy could drive market moves.
RegMed/Cell and Gene Therapy Earnings Scorecard Q1/21 LPS Results … thirty (32 – MESO added) to date … https://www.regmedinvestors.com/articles/11628
Monday’s evening’s recap: “winner, winner, chicken dinner. The cell and gene therapy sector closed positive again – 7 in a row and 8 of 10 in the June sessions.” … https://www.regmedinvestors.com/articles/11954
- The Nasdaq closed UP +104.72 points (+0.74%);
- The IBB closed down -0.17% and XBI closed up +0.63%
- Sector volume was LOW with 4 of the 18-upside having higher than the 3-month average volume with the volume of 5 of 14-downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) was up +0.74 points or +4.73% at 16.38
- Monday’s percentage (%) of the 18-upside were +0.25% (FATE) to +5.11% (VSTM) while the 14-downside ranges from –0.09% (SGMO) to -7.90% (SAGE);
Q2/21:
June: 8 positive and 2 negative closes
May: 8 positive, 12 negative closes and 1 holiday
April: 11 negative and 10 positive closes
Q1/21:
- March: 10 positive, 12 negative and 1 neutral closes
- February: 9 positive, 10 negative closes and 1 holiday
- January: 10 positive, 9 negative closes and 1 holiday
Companies in my headlights – It’s your decision; I provide an idea and context:
The Biostage (BSTG) - Maintaining Sell – It’s about saying WHAT NEEDS to be written …
Biostage (BSTG) closed flat at $1.5 with 2,305 shares traded after Friday’s +$0.04 with 1,395 shares traded to $1.25, Thursday’s +$0.01 to $1.21 with 1,325 shares traded and Wednesday’s +$0.13 to $1.26 with 1,216 shares traded.
Question#`1: Notice the volume numbers per session? WHY the need to “pump, promote and inflate” the share price; does the volume reflects the manipulation to execute the last remaining warrants?
Question#2: will the annual meeting result in ANY news to/about the future of the company?
Question#3: WHY do I keep writing on BSTG – I was there and saw WHAT they DID, WERE, KEPT on doing and CONTINUE to do and then SUDDENLY I wasn’t (there through NO fault of my own other than to UPHOLD the law) - but, the REAL question to be ANSWERED is WHO is advising them in ALL of these endeavors?
MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.
The morning’s indications:
BUY:
Applied Genetic Technologies (AGTC) closed up +$0.02 to $4.28 and has a positive +$0.25 or +5.84% pre-market indication.
uniQure NV (QURE) closed down -$1.17 to $34.89 and has a positive +$1.11 or =3.18% aftermarket indication.
Verastem VSTM) closed up +$0.23 to $4.73 and has a positive +$0.11 or +2.33% pre-market indication.
Maintaining BUY:
Cellectis SA (CLLS) closed up +$0.62 to $15.80 after Friday’s -$0.12 to $15.18 and has a positive +$0.44 or +2.78% pre-market indication.
Buy from SELL:
Global Blood Therapeutics (GBT) closed down -$0.36 to $40.28 after Friday’s -$1.03 to $40.64 with a positive +$0.71 or +1.76% aftermarket indication.
SELL:
Sage Therapeutics (SAGE) closed down -$6.25 to $72.86 and has a negative -$10.86 or -14.91% pre-market indication. SAGE said its experimental depression drug showed a statistically significant improvement in symptoms in a late-stage study after two-weeks of therapy compared to placebo.
The BOTTOM LINE: As we head through these summer months, the cell and gene therapy sector has good clinical results or it doesn’t…. for these valuations “TO STICK”.
News always helps the flow of share pricing however; higher share prices are just temporary or are they about to be deflated?
Wake-up volatility is NOT going away!
I continue to MAINTAIN, this is a confused sector as sentiment rages and fades, momentum is usurped, fundamentals are being ignored – or is it a test of our staying power in certain equities.
It’s going be a long hot summer – expects the fizzle from electronic algorithmic trading until it isn’t!
Although, “I would consider new highs … to be SOLD into …complacency is in store as many investors actually get out to vacations (one indicator).”
A true contrarian thought …
My focus has always been “warning analysis” … my advice, trim and skim any new highs if one can!” I also see a number of lows that could be in the “pick-up” stock game.
My motto, never leave an investor uninformed about what I know!
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
